Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free transvaginal mesh cases. Here at Leading Justice, we can custom-tailor your firm’s vaginal mesh advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of transvaginal mesh advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it’s eligible for another type of claim. By using innovative approaches to target contacts specifically related to transvaginal mesh and side effects like mesh erosion and infection, Leading Justice will increase your firm’s surgical mesh case load. If you are interested in helping victims of alleged transvaginal mesh side effects, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in how we classify claims as qualified or not. With our experience working alongside plaintiff law firms, we know what a great case looks like, but we will customize our transvaginal mesh case intake specifications to the exact criteria you are seeking. So, if your firm has specific surgical mesh qualifying case criteria you would like us to use, we will train our intake specialists to apply the criteria to each phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of vaginal mesh data with zero chance of fraud.
Our Take on Transvaginal Mesh
Many women who have received a transvaginal mesh implant for pelvic organ prolapse (POP) or stress urinary incontinence (SUI) are now pursing compensation for life-altering side effects like mesh erosion, infection, urinary problems and other complications requiring revision surgery. In 2008, the FDA issued a public health advisory notifying consumers about the complications associated with surgical mesh devices used to treat SUI and POP. At that point in time, the FDA had already received more than 1,000 reports over the previous three years from nine surgical mesh manufacturers of serious problems with transvaginal mesh devices.
Tens of thousands of surgical mesh lawsuits have already been filed against mesh manufacturing companies, and millions of dollars have been recovered by plaintiffs suffering from severe post-surgical complications potentially linked to transvaginal mesh. In 2011, the FDA issued a warning to consumers indicating that it is not clear that POP repair with transvaginal mesh is more effective than traditional non-mesh repair, and may actually put patients at a greater risk of complications and injury. As new information about surgical mesh risks continually comes to light, the transvaginal mesh litigation is expected to grow considerably.